Increased Risk of Hypertension with Enzalutamide in Prostate Cancer: a Meta-Analysis.

Increased Risk of Hypertension with Enzalutamide in Prostate Cancer: a Meta-Analysis. Cancer Invest. 2019 Sep 26;:1-24 Authors: Zhu X, Wu S Abstract Hypertension is associated with enzalutamide in the treatment of prostate cancer. We performed a meta-analysis of randomized clinical trials to determine the risk of hypertension. Databases including Pubmed and Google scholar were searched to identify randomized clinical trials with enzalutamide. A total of seven studies including 7,347 patients were selected. The overall incidences of all-grade and high-grade hypertension were 11.9% (95%% CI: 8.8-16.0%) and 4.9% (95%% CI: 3.5-6.8%) respectively, with a relative risk of 2.82 (95%% CI: 2.34-3.38, P < 0.001) for all-grade and 2.27 (95%% CI: 1.73-2.96, P < 0.001) for high-grade. There was a significant risk of developing hypertension with enzalutamide. PMID: 31557062 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research